VSGP/F-spondin: A new ovarian cancer marker
VSGP/F-spondin: A new ovarian cancer marker
复制标题
DOI：
10.1159/000087379
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Xu, JC
中科院分区：
文献类型：
--
作者：
Pyle-Chenault, RA;Stolk, JA;Xu, JC
卵巢癌中过表达基因的发现为卵巢癌生物学提供了有价值的见解，并将导致开发更有效的治疗策略来对抗这种疾病。为了鉴定卵巢癌和卵巢癌特异性表达的基因，我们从原发性和转移性卵巢腺癌组织中制备了四个消减cDNA文库。使用来自各种正常组织和卵巢肿瘤组织的32对荧光团标记的cDNA样品，通过微阵列分析来自这些文库的3，400个cDNA克隆的组织分布和肿瘤特异性。通过DNA测序与公共数据库比较，鉴定在卵巢肿瘤中表达升高的cDNA克隆，并通过定量实时聚合酶链反应和北方印迹进一步分析最有希望的候选者。这种系统的方法导致了一些基因的鉴定，包括血管平滑肌生长促进因子（VSGP/F-spondin），一种分泌蛋白，以前确定和克隆牛和人类卵巢。VSGP/F-spondin蛋白在卵巢癌组织中表达，而在正常卵巢上皮组织中未表达。VSGP/F-spondin的表达谱鉴定了该分子作为开发治疗卵巢癌的治疗策略的潜在诊断标志物或靶标。版权所有（C）2005 S. Karger AG，巴塞尔。
The discovery of genes that are overexpressed in ovarian cancers provides valuable insight into ovarian cancer biology and will lead to the development of more effective treatment strategies for combating this disease. To identify genes exhibiting ovarian- and ovarian cancer-specific expression, we generated four subtracted cDNA libraries from primary and metastatic ovarian adenocarcinoma tissues. 3,400 cDNA clones from these libraries were analyzed by microarray for tissue distribution and tumor specificity using 32 pairs of fluorophore-labeled cDNA samples from a variety of normal tissues and ovarian tumor tissues. cDNA clones showing elevated expression in ovarian tumors were identified by DNA sequencing with comparison to public databases, and the most promising candidates were further analyzed by quantitative real-time polymerase chain reaction and Northern blot. This systematic approach led to the identification of a number of genes including vascular smooth muscle growth-promoting factor (VSGP/F-spondin), a secreted protein previously identified and cloned from bovine and human ovary. VSGP/F-spondin protein was observed in ovarian carcinomas but not in normal ovarian epithelium by immunohistochemistry with a VSGP/F-spondin antibody. The expression profile of VSGP/F-spondin identifies this molecule as a potential diagnostic marker or target for developing therapeutic strategies to treat ovarian carcinoma. Copyright (C) 2005 S. Karger AG, Basel.